{"id":15193,"date":"2021-03-26T10:00:21","date_gmt":"2021-03-26T09:00:21","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15193"},"modified":"2021-03-26T10:00:21","modified_gmt":"2021-03-26T09:00:21","slug":"approbation-de-lidecabtagene-vicleucel-par-la-fda","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/approbation-de-lidecabtagene-vicleucel-par-la-fda\/","title":{"rendered":"Approbation de l&#8217;idecabtagene vicleucel par la FDA"},"content":{"rendered":"<p>Bristol Myers Squibb (NYSE : BMY) et bluebird bio, Inc., ont annonc\u00e9 que la <em>Food and Drug Administration<\/em>(FDA) a approuv\u00e9 l&#8217;idecabtagene vicleucel; ide-cel \u00e9galement appel\u00e9bb2121pour le traitement des patients adultes en rechute ou pour un my\u00e9lome multiple r\u00e9fractaire apr\u00e8s quatre lignes de traitement ou plus, y compris un agent immunomodulateur, un inhibiteur de prot\u00e9asome et un anticorps monoclonal anti-CD38. Idecabtagene vicleucel est une th\u00e9rapie cellulaire immunitaire personnalis\u00e9e approuv\u00e9e comme perfusion unique<sup>1<\/sup>. En tant que th\u00e9rapie cellulaire CAR T anti-BCMA, l&#8217;idecabtagene vicleucel reconna\u00eet et se lie au BCMA, une prot\u00e9ine qui est presque universellement exprim\u00e9e sur les cellules canc\u00e9reuses dans le my\u00e9lome multiple, entra\u00eenant la mort des cellules exprimant BCMA<sup>2<\/sup>.<\/p>\n<p>Bristol Myers Squibb est d\u00e9sormais la seule entreprise avec deux th\u00e9rapies cellulaires CAR T approuv\u00e9es, ciblant CD19 et BCMA.<\/p>\n<p><em>\u00a0<\/em><\/p>\n<ol>\n<li><em> idecabtagene vicleucel Prescribing Information. Bristol Myers Squibb; March 2021.<\/em><\/li>\n<li><em> Cho, S.F., Anderson, K., Tai, Y.T. (2018). Targeting B Cell Maturation Antigen (BCMA) in<\/em><\/li>\n<\/ol>\n<p><em>Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. <\/em><em>Frontiers in<\/em><\/p>\n<p><em>Immunology, (9)1821. 1-15.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Bristol Myers Squibb (NYSE : BMY) et bluebird bio, Inc., ont annonc\u00e9 que la Food and Drug Administration(FDA) a approuv\u00e9 l&#8217;idecabtagene vicleucel; ide-cel \u00e9galement appel\u00e9bb2121pour le traitement des patients adultes [&hellip;]<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[442],"class_list":["post-15193","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15193"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15193\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15193"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}